White House Announces Actions to Lower Costs and Expand Access to IVF Services

On Oct. 16, President Trump announced a MFN deal with EMD Serono. Similar to the previously announced Pfizer and AstraZeneca deals, the agreement includes the following components: 1) providing every state Medicaid program access to MFN prices on most products, 2) guaranteeing MFN prices on all new-to-market products, 3) offering certain medicines at a discounted price when selling directly to Americans through TrumpRx, and 4) provide a three-year tariff exemption to the manufacturer in exchange for investments in U.S. manufacturing and research and development.

The announcement focused on EMD Serono’s fertility therapies as the administration used the new deal to outline additional actions it was taking to expand access to in vitro fertilization (IVF) treatments, including an accelerated review of EMD Serono’s new lower-cost fertility drug and new legal pathways for employers to offer fertility benefits as an “excepted benefit,” similar to dental, vision, and life insurance.

Evernorth’s specialized fertility pharmacies (Freedom Fertility and VFP Pharmacy) were named as pharmacy partners for TrumpRx, anticipated to launch in 2026. In conjunction with the launch of TrumpRx, Evernorth will dispense EMD Serono treatments for infertility (GONAL-f, Cetrotide, and Ovidrel) purchased through the platform at a low cost, combined cash price, which will be the lowest in the market.